Table 1.
Patient clinical and microbiological characteristics at baseline treated with oral fosfomycin-trometamol.
| UTI | Patient/UTI Episodes | Age | Charlson Comorbidity Index/Immunosuppression | Urological Disorder/Creatinine * (umol/liter) | Clinical Features | CRP (mg/L)/Acute Kidney Failure | Bacteriuria/ ATS/ Fosfomycin MIC |
Preliminary Antibiotics | Oral FT (Dosing, Duration) | Recovery (Clinical/ Microbiological) |
Follow-Up ** (Recurrence/ITU New Episode) |
Adverse Effects | Microbiological Colonization |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute UTI | 1 | 61 | 2/No | BPH***/88 | Fever UFD |
NR/83 | E. coli 107/ESBL, FQ R, SMX-TMP R/ND | FQ (2days) | 3 g/24 h, 1 w | Yes/ND | 0/0 | Minor diarrhea | ND |
| 2 | 76 | 9/No | Non/56 | Fever UFD, lower back pain |
300/28 | E. coli 106/ESBL, FQ R, SMX-TMP R/ND | NTF (1day) | 3 g/24 h, 3 w | Yes/Yes | 0/0 | No | No | |
| 3 | 69 | 3/No | BPH/73 | Fever UFD |
160/60 |
E. coli 107/ESBL, FQ R, SMX-TMP R/ND |
FQ (2days) AMC (2days) |
3 g/24 h, 3 w | Yes/Yes | 0/0 | No | No | |
| 4 | 38 | 0/No | Non/90 | UFD | <5/88 | K. pneumoniae 105/penicillinase, FQ R, SMX-TMP R/24 | SMX-TMP (5days) | 3 g/24 h, 3 w | Yes/Yes | 0/0 | Minor diarrhea | No | |
| Chronic bacterial prostatitis | 5 | 69 | 2/No | BPH, prostatic calcifications/86 | UFD | 170/74 | E. coli 105/penicillinase, FQ R, SMX-TMP R/ND | SMX-TMP (10days) |
3 g/24 h, 3 w | Yes/Yes | 0/0 | Moderate diarrhea | No |
| 6/1st UTI | 79 | 5/No | Prostatic adenocarcinoma/65 | UFD | NR | E. coli 106/ESBL, FQ R, SMX-TMP R/ND | No | 3 g/24 h, 3 w | Yes/Yes | 2 (M1, M3)/0 | Non | No | |
| 6/2nd UTI | UFD | NR | E. coli 106/ESBL, FQ R, SMX-TMP R/ND | No | 3 g/24 h, 3 w 3 g/48 h, 3 w |
Yes/Yes | 0/0 | Minor diarrhea | No | ||||
| 7 | 83 | 10/No | Prostatic adenocarcinoma/47 | UFD | NR | E. coli 106/ESBL, FQ R, SMX-TMP R/ND | No | 3 g/24 h, 3 w | Yes/ND | 0/0 | Non | No | |
| 8 | 68 | 10/No | BPH, prostatic calcifications/69 | Fever UFD |
NR | E. coli 107/ESBL, FQ R, SMX-TMP R/ND | No | 3 g/24 h, 2 w 3 g/48 h, 4 w |
Yes/Yes | 1 (M2)/0 | Non | No | |
| 9 | 76 | 7/Renal transplantation | Vesicoureteral reflux, HBP/36 | UFD | 20/33 | K. pneumoniae 105/ESBL, FQ R, SMX-TMP R/96 | No | 3 g/24 h, 3 w 3 g/48 h, 3 w |
No/No | 2 (W1, M3)/2 (M1, M2) | Non | No | |
| 10 | 67 | 7/Cirrhosis | BPH, bladder disorders/95 | UFD | 40/104 | K. pneumoniae 107/ESBL, FQ R, SMX-TMP R/32 | No | 3 g/24 h, 3 w 3 g/48 h, 3 w |
Yes/Yes | 2 (M1, M4)/0 | Non | Yes, (W1, MIC 16mg/L) | |
| 11 | 53 | 2/Systemic Lupus Erythematosus | BPH/102 | UFD | <5/102 | E. coli 106/ESBL, FQ R, SMX-TMP R/ND | No | 3 g/24 h, 3 w 3 g/48 h, 3 w |
Yes/Yes | 0/0 | Minor diarrhea | Non | |
| 12/1st UTI | 75 | 3/No | BPH/71 | Fever UFD |
<5/63 |
E. coli 105/ESBL, FQ R, SMX-TMP R/ND |
NTF (21days) | 3 g/24 h, 3 w 3 g/48 h, 3 w |
Yes/Yes | 1 (W2)/0 | Non | Non | |
| 12/2nd UTI | UFD | NR | E. coli 105/ESBL, FQ R, SMX-TMP R/ND | No | 3 g/24 h, 3 w 3 g/48 h, 3 w |
Yes/Yes | 0/0 | Non | Non | ||||
| 13 | 45 | 3/No | Bladder disorders/105 | Fever UFD |
10/73 | E. coli 106/penicillinase, FQ R, SMX-TMP R/ND | SMX-TMP (7 days) |
3 g/24 h, 3 w | Yes/ND | 0/1 (M4) | Non | Non | |
| 14 | 59 | 3/No | BPH, testicular implant/97 | Fever UFD |
NR/95 | E. coli 105/ESBL, FQ R, SMX-TMP R/ND | No | 3 g/24 h, 3 w 3 g/48 h, 3 w |
Yes/ND | 0/2 (M2, M3) | Moderate diarrhea | Non | |
| 15/1st UTI | 71 | 3/No | BPH/79 | Fever UFD |
<5/81 | E. coli 106/FQ R, SMX-TMP R/ND | No | 3 g/24 h, 2 w 3 g/48 h, 4 w |
Yes/ND | 1 (M6)/0 | No | ND | |
| 15/2nd UTI | Fever |
NR | E. coli 106/FQ R, SMX-TMP R/2 | No | 3 g/24 h, 3 w 3 g/48 h, 9 w |
Yes/Yes | 0/0 | No | Yes (M3) | ||||
| 16/1st UTI | 69 | 6/Systemic Lupus Erythematosus, pulmonary transplantation | Urinary bladder carcinoma, bladder disorders/55 | UFD | 20/46 | K. pneumoniae 107/ESBL, FQ R, SMX-TMP R/ND | NTF (10 days) | 3 g/24 h, 3 w 3 g/48 h, 3 w |
Yes/ND | 1 (M6)/0 | No | NR | |
| 16/2nd UTI | UFD | NR | K. pneumoniae 103/ESBL, FQ R, SMX-TMP R/ND | No | 3 g/24 h, 3 w 3 g/48 h, 3 w |
Yes/Yes | 1 (M3)/0 | No | Non | ||||
| 16/3rd UTI | UFD | NR | K. pneumoniae 105/ESBL, FQ R, SMX-TMP R/ND | No | 3 g/24 h, 1 w 3 g/48 h, 2 w |
Yes/Yes | 0/0 | No | Non |
Abbreviations: UTI: Urinary Tract Infection, BPH: Benign Prostate Hyperplasia, UFD: Urinary functional disorders, CRP: C-reactive protein, ATS: Antimicrobial Susceptibility Testing, MIC: Minimum Inhibitory Concentration, R: Resistence, ESBL: extended spectrum beta-lactamase, FQ: fluoroquinolones, SMX-TMP: trimethoprim/sulfamethoxazole, ND: not done, NTF: nitrofurantoin, AMC: amoxicillin-clavulanate, CFX: cefixime, FT: fosfomycin-trometamol, W: week, M: Month. * CKD (ml/min/1,73m2), ** Follow up M6: except for patient 4 (3M), patient 8 (4M), patient 12 UI 2 (4M), patient 16 UI 3 (1M).